Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation.
Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product’s high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as actinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as “the future of cancer treatment”. Rosatom and healthcare facilities are actively working in this field.
“Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science,” said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC.
The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.
